OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.
More OpGen content >Investment summary
OpGen is a diagnostic company focused on revolutionizing the identification and treatment of bacterial infections. It recently merged with Curetis, a Germany-based molecular diagnostics company with a complementary focus on infectious disease. Curetis has two main business lines: the Unyvero A50 high-plex polymerase chain reaction platform for the diagnosis of infectious disease in hospital patients and the ARES AMR database (ARESdb), which includes data on 55,000 sequenced strains with a focus on resistant pathogens, as well as data on over 100 antibiotics.
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2019A | 3.5 | (11.7) | (11.9) | (737.57) | N/A | N/A |
| 2020A | 4.2 | (22.0) | (25.3) | (157.41) | N/A | N/A |
| 2021E | 10.5 | (20.9) | (25.5) | (70.43) | N/A | N/A |
| 2022E | 26.4 | (11.8) | (14.1) | (34.69) | N/A | N/A |
Industry outlook
It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.
Last updated on 06/04/2021Content on OpGen
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (US$m) | 3.8 |
| Forecast gearing ratio (%) | 15 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Oliver Schacht | CEO |
| Tim Dec | CFO |